Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil, Thalidomide, and Dexamethasone in Previously Untreated Multiple Myeloma
NCT00222105Phase 2Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Nov 2002
- Primary completion
- Apr 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in multiple myeloma (MM), sponsored by University of Kansas Medical Center. Primary endpoint: Overall Response Rate at 28 days. Started Nov 2002; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00222105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00222105.